TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
RXRX

Recursion Pharmaceuticals Inc

Healthcare · Biotechnology

3.80$ +8.2% vs. previous close Closing price · As of: Sep 18, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement RXRX
Line item 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0%
2,677.3% 1,855.2% 91.0% 121.7% 97.1% 76.9% 162.0%
-2,577.3% 100.0% 100.0% -21.7% 2.9% 23.1% -62.0%
2,677.3% 1,855.2% 1,352.7% 392.4% 549.8% 534.4% 569.4%
1,107.6% 740.1% 576.8% 205.6% 252.6% 302.8% 236.5%
3,749.4% 2,579.2% 1,927.8% 597.6% 800.8% 837.2% 805.9%
-3,649.4% -2,479.2% -1,827.8% -619.3% -797.8% -814.1% -867.9%
37.1% 39.8% 29.5% 0.1% 0.2% 2.7% 2.4%
-3,616.5% -2,549.3% -1,864.8% -603.5% -757.0% -789.9% -863.5%
37.8% 25.7% -84.1% -0.1% -9.3% -1.9% -0.2%
-3,654.3% -2,549.3% -1,780.7% -603.4% -747.7% -788.0% -863.4%
-3,409.5% -2,393.9% -1,743.7% -589.6% -701.1% -725.2% -749.0%

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?